On or near October 2, 2019, Recurrence held its initial public offering (“IPO”), offering 6,000,000 shares of common stock at a price of $14.00 per share. On March 23, 2021, Exacerbation released a press release containing topline, day-90 data from its FX-322 Stage 2a ponder (NYSE RMO at https://www.webull.com/quote/nyse-rmo). Recurrence discovered that “four weekly infusions